The ACER1 Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the UM-UC-3 human urothelial carcinoma cell line, with targeted disruption of ACER1 leading to abrogation of alkaline ceramidase activity. This heterogeneous loss-of-function model avoids clonal selection bias and is suitable for studying the functional consequences of ACER1 ablation.
The UM-UC-3 cell line is a well-characterized model of invasive bladder carcinoma, originally derived from a transitional cell carcinoma of the urinary bladder. Notably, UM-UC-3 carries a TP53 missense mutation (R175H), which compromises p53 tumor suppressor function and contributes to genomic instability and altered apoptotic responses. This genetic context makes UM-UC-3 a relevant platform for investigating oncogenic signaling and therapeutic vulnerabilities in bladder cancer.
The ACER1 gene encodes an alkaline ceramidase that hydrolyzes ceramides to sphingosine and fatty acids, a critical step in sphingolipid metabolism. Its activity is influenced by upstream signals including p53, EGFR signaling, and TNF-??. The product sphingosine is phosphorylated by sphingosine kinases SPHK1/2 to generate sphingosine-1-phosphate (S1P), which exerts pro-survival effects via S1P receptors (S1PR1?C5) and downstream activation of MAPK/ERK and PI3K/AKT pathways. Ceramide synthases and sphingomyelinase contribute to the ceramide pool, positioning ACER1 at a key node of the ceramide/S1P rheostat that governs cell fate decisions.
Disruption of ACER1 in UM-UC-3 cells is expected to block ceramide degradation, leading to ceramide accumulation and reduced flux toward sphingosine and S1P. In the TP53-mutant background, where intrinsic apoptotic pathways may be compromised, elevated ceramide levels could lower the apoptotic threshold or reveal synthetic vulnerabilities. Concurrently, attenuated S1P production may diminish MAPK/ERK and PI3K/AKT-driven proliferation, migration, and drug resistance. This model thus enables dissection of the crosstalk between p53 status and sphingolipid metabolism in bladder cancer and facilitates the study of resistance mechanisms to therapies such as cisplatin.
Researchers can employ this ACER1 knockout polyclonal population to investigate ceramide-mediated apoptosis, sphingolipid metabolic flux, and signal transduction pathways using a variety of assays such as western blotting, RT-qPCR, lipidomics (LC-MS for ceramide species profiling), apoptosis assays (e.g., Annexin V staining), proliferation assays (MTS), and migration assays (Transwell). The polyclonal nature enables population-level analyses without clonal selection artifacts, making it ideal for drug sensitivity screening and functional genomics studies in cancer biology. For further information and order inquiries, please contact Ascent Research.
